RESEARCHER PROFILE

David A Nolan

← Back to Dublin City University

D

Dublin City University

HIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV Research and TreatmentDrug-Induced Adverse ReactionsHIV/AIDS Research and Interventions

David A Nolan works in HIV/AIDS drug development and treatment, HIV-related health complications and treatments, HIV Research and Treatment, Drug-Induced Adverse Reactions, HIV/AIDS Research and Interventions. Recorded institutional associations include Dublin City University.

213Publications
9,704Citations
45H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. HLA-B*5701 Screening for Hypersensitivity to Abacavir

    2008 · 1,835 citations
  2. Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

    2002 · 1,380 citations
  3. Predisposition to abacavir hypersensitivity conferred by HLA-B * 5701 and a haplotypic Hsp70-Hom variant

    2004 · 452 citations
  4. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease

    2006 · 388 citations
  5. Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity

    2008 · 334 citations
  6. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

    2004 · 317 citations
  7. Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study

    2006 · 296 citations
  8. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

    2003 · 265 citations
  9. Clinical and immunogenetic correlates of abacavir hypersensitivity

    2005 · 198 citations
  10. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

    2001 · 163 citations
  11. Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation

    2006 · 132 citations
  12. Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level

    2003 · 129 citations
  13. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression

    2005 · 128 citations
  14. Randomized, Controlled, 48-Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV-Infected Patients

    2003 · 112 citations
  15. Metabolic Complications Associated with HIV Protease Inhibitor Therapy

    2003 · 97 citations
  16. Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms

    2004 · 96 citations
  17. Antiretroviral Therapy and the Lipodystrophy Syndrome

    2001 · 95 citations
  18. Interferon‐alpha, immune activation and immune dysfunction in treated HIV infection

    2014 · 95 citations
  19. Oestrogen replacement therapy may improve memory functioning in the absence of APOE ε4

    2004 · 94 citations
  20. Accumulation of Mitochondrial DNA Mutations in Human Immunodeficiency Virus–Infected Patients Treated with Nucleoside-Analogue Reverse-Transcriptase Inhibitors

    2003 · 93 citations
  21. HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection

    2013 · 90 citations
  22. Mitochondrial Proliferation, Dna Depletion and Adipocyte Differentiation in Subcutaneous Adipose Tissue of HIV-Positive Haart Recipients

    2003 · 84 citations
  23. Plasma Aβ42 correlates positively with increased body fat in healthy individuals

    2005 · 75 citations
  24. A Visfatin Promoter Polymorphism Is Associated with Low‐Grade Inflammation and Type 2 Diabetes

    2006 · 75 citations
  25. Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins

    2010 · 74 citations

← Return to the university profile